Clinical Report: Considerations for Clinical Trial Sites

Overview

This report outlines the key metrics used by sponsors and CROs to evaluate clinical trial sites, emphasizing the importance of operational maturity and patient population access. Effective site selection is crucial for timely study completion and regulatory success.

Background

Clinical trials are essential for advancing ophthalmology, with a growing demand for high-performing research sites. The selection of appropriate sites is a strategic decision that impacts study timelines, costs, and data integrity. Underperforming sites can lead to recruitment delays and jeopardize the approval of therapies, making it vital for sites to align with sponsor expectations.

Data Highlights

No numerical data available in the source material.

Key Findings

• Access to the right patient population is a decisive factor in site selection.
• Underperforming sites can lead to delays in recruitment and increased operational burdens.
• Honesty in enrollment projections is critical for timely study completion.
• Sites must align with FDA guidance on diversity to enhance their appeal to sponsors.
• Operational maturity and training are essential for maintaining data integrity and meeting regulatory endpoints.

Clinical Implications

Clinicians and site managers should focus on building robust patient databases and referral networks to enhance site selection prospects. Training staff adequately and ensuring operational maturity can mitigate risks associated with underperformance in clinical trials.

Conclusion

Effective site selection is paramount for the success of clinical trials in ophthalmology, influencing both study outcomes and the timely delivery of innovative therapies to patients.

References

1. Ophthalmology Management, 2025 -- Bring Clinical Research Into Your ASC
2. The ASCO Post, 2018 -- How to Build a Clinical Trial Infrastructure in the Community Oncology Setting
3. E6(R3) Good Clinical Practice (GCP) | FDA
4. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - PubMed
5. CTTI Recommendations: Use of Real-World Data to Plan Eligibility Criteria and Enhance Recruitment
6. ophthalmology management — Bring Clinical Research Into Your ASC
7. Ophthalmology Management — Boost Your Practice With Clinical Trials
8. E6(R3) Good Clinical Practice (GCP) | FDA
9. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - PubMed
10. CTTI Recommendations: Use of Real-World Data to Plan Eligibility Criteria and Enhance Recruitment - CTTI